image
Healthcare - Medical - Diagnostics & Research - NASDAQ - DE
$ 0.2387
-4.52 %
$ 5.22 M
Market Cap
-0.22
P/E
1. INTRINSIC VALUE

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.[ Read More ]

The intrinsic value of one MYNZ stock under the base case scenario is HIDDEN Compared to the current market price of 0.239 USD, Mainz Biomed B.V. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart MYNZ

image
FINANCIALS
895 K REVENUE
69.00%
-26.6 M OPERATING INCOME
-1.80%
-26.3 M NET INCOME
0.35%
-21.9 M OPERATING CASH FLOW
-48.54%
-1.9 M INVESTING CASH FLOW
-188.37%
14.2 M FINANCING CASH FLOW
-40.58%
215 K REVENUE
18.22%
-6.59 M OPERATING INCOME
-16.84%
-5.18 M NET INCOME
17.72%
-4.66 M OPERATING CASH FLOW
28.44%
-374 K INVESTING CASH FLOW
-232.76%
3.47 M FINANCING CASH FLOW
-24.13%
Balance Sheet Decomposition Mainz Biomed B.V.
image
Current Assets 8.98 M
Cash & Short-Term Investments 7.07 M
Receivables 355 K
Other Current Assets 1.55 M
Non-Current Assets 6.43 M
Long-Term Investments 0
PP&E 3.03 M
Other Non-Current Assets 3.39 M
Current Liabilities 9.24 M
Accounts Payable 2.33 M
Short-Term Debt 5.22 M
Other Current Liabilities 1.69 M
Non-Current Liabilities 2.92 M
Long-Term Debt 2.2 M
Other Non-Current Liabilities 727 K
EFFICIENCY
Earnings Waterfall Mainz Biomed B.V.
image
Revenue 895 K
Cost Of Revenue 386 K
Gross Profit 510 K
Operating Expenses 27.2 M
Operating Income -26.6 M
Other Expenses -349 K
Net Income -26.3 M
RATIOS
56.91% GROSS MARGIN
56.91%
-2975.47% OPERATING MARGIN
-2975.47%
-2936.50% NET MARGIN
-2936.50%
-809.29% ROE
-809.29%
-170.65% ROA
-170.65%
-289.12% ROIC
-289.12%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Mainz Biomed B.V.
image
Net Income -26.3 M
Depreciation & Amortization 866 K
Capital Expenditures -1.9 M
Stock-Based Compensation 4.01 M
Change in Working Capital -64.6 K
Others -751 K
Free Cash Flow -23.8 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Mainz Biomed B.V.
image
MYNZ has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Mainz Biomed B.V.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update Revenue increases 4% year over year while loss from operations decreases by 32% Pooled Results of ColoFuture and eAArly DETECT studies published at ASCO showing groundbreaking performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Company highlights its path to success for 2025 BERKELEY, Calif. and MAINZ, Germany, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. globenewswire.com - 3 weeks ago
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version; GANZIMMUN Diagnostics to Feature ColoAlert globenewswire.com - 1 month ago
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025 BERKELEY, Calif. and MAINZ, Germany, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. globenewswire.com - 1 month ago
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience BERKELEY, Calif. and MAINZ, Germany, July 25, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. globenewswire.com - 3 months ago
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test On the basis of its positive clinical studies Mainz Biomed has now defined the final configuration including its novel mRNA biomarkers of the Next Generation Test to be used in pivotal registration study ReconAAsense A recent clinical analysis of this new configuration demonstrates sensitivity for colorectal cancer of 97% and 88% for advanced adenomas, with specificity of 93% BERKELEY, Calif. and MAINZ, Germany, July 09, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. globenewswire.com - 4 months ago
Mainz Biomed Provides Half Year 2024 Corporate Update BERKELEY, Calif. and MAINZ, Germany, July 02, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. globenewswire.com - 4 months ago
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024 New study data confirmed previous ColoFuture and eAArly DETECT study performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Results from pooled study represents the third consecutive confirmation of the consistently good performance of Mainz Biomed's mRNA biomarkers to detect CRC and precancerous lesions BERKELEY, Calif. and MAINZ, Germany, June 03, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. globenewswire.com - 5 months ago
Mainz Biomed Reports Results of 2024 Annual General Meeting BERKELEY, Calif. and MAINZ, Germany, May 31, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. globenewswire.com - 5 months ago
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting Key Findings: 92.3% Sensitivity for Colorectal Cancer, 82.3% for Advanced Precancerous Lesions Poster presentation showing new data on 690 subjects including previously unexamined and unreported samples from the pooled ColoFuture and eAArly DETECT studies utilizing the mRNA biomarkers, FIT test, and a proprietary AI Algorithm BERKELEY, Calif. and MAINZ, Germany, May 28, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. globenewswire.com - 5 months ago
Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial Mainz Biomed Presented Industry Leading Results: 97% Sensitivity for Colorectal Cancer, 82% for Advanced Precancerous Lesions The eAArly DETECT results demonstrated that within the advanced precancerous lesion patients, 100% of those patients with high grade dysplasia were detected The Company's mission is to transform current colorectal cancer screening practices, and ultimately to reduce cancer mortality rates worldwide by shifting from cancer detection to cancer prevention BERKELEY, Calif. and MAINZ, Germany, May 20, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. globenewswire.com - 5 months ago
8. Profile Summary

Mainz Biomed B.V. MYNZ

image
COUNTRY DE
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 5.22 M
Dividend Yield 0.00%
Description Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Contact Robert Koch Strasse 50, Mainz, 55129 https://mainzbiomed.com
IPO Date Nov. 5, 2021
Employees 65
Officers Mr. Guido Baechler Chief Executive Officer & Executive Director Dr. Christopher Von Torne P.M.P., Ph.D. Chief Operating Officer Dr. Frank Krieg-Schneider Chief Technology Officer Dr. Moritz Eidens Ph.D. Chief Science Officer & Executive Director Stefan Erlach Head of Human Resources Mr. Philipp Freese Chief Business Officer